Twist Bioscience Corporation $TWST Stock Holdings Lessened by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. lessened its position in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 75.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,481 shares of the company’s stock after selling 74,770 shares during the period. Mawer Investment Management Ltd.’s holdings in Twist Bioscience were worth $4,731,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. E. Ohman J or Asset Management AB acquired a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $853,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience during the 1st quarter worth $22,563,000. Bank of America Corp DE boosted its stake in shares of Twist Bioscience by 46.3% in the 1st quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock valued at $27,764,000 after purchasing an additional 184,907 shares in the last quarter. William Blair Investment Management LLC bought a new stake in shares of Twist Bioscience during the second quarter worth $223,722,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Twist Bioscience in the 2nd quarter worth about $8,215,000.

Insider Activity at Twist Bioscience

In other news, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the sale, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. The trade was a 8.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 9,514 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the sale, the insider directly owned 63,789 shares of the company’s stock, valued at approximately $12,048,466.32. This represents a 12.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 495,279 shares of company stock valued at $80,489,387 in the last ninety days. 3.08% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Robert W. Baird dropped their price target on shares of Twist Bioscience from $187.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. TD Cowen dropped their price target on Twist Bioscience from $190.00 to $137.00 and set a “buy” rating on the stock in a research note on Friday. Guggenheim raised their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Finally, BWS Financial reaffirmed a “sell” rating and set a $45.00 target price on shares of Twist Bioscience in a research report on Friday, September 18th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of “Hold” and a consensus price target of $141.00.

Check Out Our Latest Research Report on TWST

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $111.60 on Monday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71. The company’s 50-day moving average is $150.23 and its 200 day moving average is $93.07. The company has a market capitalization of $7.00 billion, a P/E ratio of -53.40 and a beta of 2.25. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $126.64 million during the quarter, compared to the consensus estimate of $123.55 million. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business’s revenue was up 26.7% compared to the same quarter last year. On average, equities research analysts forecast that Twist Bioscience Corporation will post -1.52 earnings per share for the current year.

Key Headlines Impacting Twist Bioscience

Here are a few of the latest headlines about TWST:

  • Positive Sentiment: Fiscal Q4 revenue rose about 27% year over year to $126.6 million, beating consensus, while the $0.32-per-share loss was narrower than analysts expected. AI drug-discovery revenue totaled $59.1 million for fiscal 2026. Article: Twist Bioscience: 3 Key Takeaways for Long-Term Investors
  • Neutral Sentiment: Fiscal 2027 revenue guidance of $550 million–$560 million is only modestly above the $549 million consensus, which may have disappointed investors looking for a stronger outlook. Article: Twist Bio slips despite Q4 beat after underwhelming FY27 outlook
  • Negative Sentiment: Leerink Partners cut its price target to $175 from $190, TD Cowen to $137 from $190, and Baird to $135 from $187. Each maintained a positive rating—outperform or buy—but the reductions indicate more cautious valuation expectations. Leerink Partners ratings

About Twist Bioscience

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

See Also

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.